DK0723538T3 - Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme - Google Patents

Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme

Info

Publication number
DK0723538T3
DK0723538T3 DK94930074T DK94930074T DK0723538T3 DK 0723538 T3 DK0723538 T3 DK 0723538T3 DK 94930074 T DK94930074 T DK 94930074T DK 94930074 T DK94930074 T DK 94930074T DK 0723538 T3 DK0723538 T3 DK 0723538T3
Authority
DK
Denmark
Prior art keywords
inhibition
treatment
compounds useful
proliferative diseases
protein function
Prior art date
Application number
DK94930074T
Other languages
Danish (da)
English (en)
Inventor
Alan K Mallams
W Robert Bishop
Ronald J Doll
F George Njoroge
Joanne M Petrin
John J Piwinski
Stacy W Remiszewski
Arthur G Taveras
Ronald L Wolin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0723538T3 publication Critical patent/DK0723538T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94930074T 1993-10-15 1994-10-12 Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme DK0723538T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13743593A 1993-10-15 1993-10-15
PCT/US1994/011391 WO1995010515A1 (en) 1993-10-15 1994-10-12 Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
DK0723538T3 true DK0723538T3 (da) 2002-03-18

Family

ID=22477422

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94930074T DK0723538T3 (da) 1993-10-15 1994-10-12 Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme

Country Status (18)

Country Link
EP (1) EP0723538B1 (cg-RX-API-DMAC7.html)
JP (1) JP2875393B2 (cg-RX-API-DMAC7.html)
AT (1) ATE210652T1 (cg-RX-API-DMAC7.html)
AU (1) AU699043B2 (cg-RX-API-DMAC7.html)
CA (1) CA2174105C (cg-RX-API-DMAC7.html)
DE (1) DE69429438T2 (cg-RX-API-DMAC7.html)
DK (1) DK0723538T3 (cg-RX-API-DMAC7.html)
ES (1) ES2164716T3 (cg-RX-API-DMAC7.html)
HU (1) HUT76066A (cg-RX-API-DMAC7.html)
IL (1) IL111258A0 (cg-RX-API-DMAC7.html)
MA (1) MA23353A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ274749A (cg-RX-API-DMAC7.html)
PT (1) PT723538E (cg-RX-API-DMAC7.html)
SG (1) SG48750A1 (cg-RX-API-DMAC7.html)
TN (1) TNSN94104A1 (cg-RX-API-DMAC7.html)
TW (1) TW308594B (cg-RX-API-DMAC7.html)
WO (1) WO1995010515A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA947970B (cg-RX-API-DMAC7.html)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703905A1 (en) * 1993-06-18 1996-04-03 Merck & Co. Inc. Inhibitors of farnesyl-protein transferase
ZA947969B (en) 1993-10-15 1996-07-12 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH11509204A (ja) * 1995-07-13 1999-08-17 ユニバーシテイ・オブ・シンシナテイ 神経線維腫症の治療に有用な化合物
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CA2240846C (en) 1995-12-22 2002-07-16 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
US6028201A (en) * 1996-01-30 2000-02-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997031641A1 (en) * 1996-02-29 1997-09-04 Duke University Method of treating hepatitis delta virus infection
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
PE92098A1 (es) 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
HUP0000191A2 (hu) * 1996-09-13 2001-04-28 Schering Corp. Farnezil-protein-transzferáz inhibitorként alkalmazható új triciklusos piperidinil-vegyületek
CA2264569C (en) * 1996-09-13 2003-11-11 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
AU4337597A (en) * 1996-09-13 1998-04-02 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein tr ansferase
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
CN1237164A (zh) * 1996-09-13 1999-12-01 先灵公司 用作法呢基－蛋白转移酶抑制剂的化合物
BR9712035A (pt) * 1996-09-13 1999-08-24 Schering Corp Compostos Úteis para inibi-Æo de transferase de prote¡na farnesila
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
NZ334453A (en) * 1996-09-13 2000-08-25 Schering Corp Tricyclic inhibitors of farnesyl protein transferase
CA2266015C (en) * 1996-09-13 2003-12-30 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
US5965570A (en) * 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
AU4892297A (en) * 1996-10-09 1998-05-05 Schering Corporation Tricyclic compounds having activity as ras-fpt inhibitors
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
US5760232A (en) * 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
WO1998057964A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
KR20010013882A (ko) * 1997-06-17 2001-02-26 둘락 노먼 씨. 파르네실 단백질 트랜스퍼라제의 억제에 유용한벤조(5,6)사이클로헵타(1,2ｂ)피리딘 유도체
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NZ501376A (en) * 1997-06-17 2002-03-28 Schering Corp 4-(6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-2-piperazine-carboxamide derivatives useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
KR20010013825A (ko) * 1997-06-17 2001-02-26 둘락 노먼 씨. 파네실 단백질 전이효소를 억제하기에 유용한비스피리도-사이클로헵탄 화합물
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
IL133446A0 (en) * 1997-06-17 2001-04-30 Schering Corp Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
CN1286690A (zh) * 1997-06-17 2001-03-07 先灵公司 用于抑制法尼基蛋白转移酶的化合物
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
US5958940A (en) * 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
JP2001519428A (ja) * 1997-10-10 2001-10-23 シェーリング コーポレイション エチル４−（８−クロロ−５，６−ジヒドロ−１１Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジン−１１−イリデン）−１−ピペリデンカルボキシレート多形物
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
WO2000001701A1 (en) 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU760027B2 (en) 1998-07-02 2003-05-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6686502B1 (en) 1999-03-26 2004-02-03 Ucb S.A. Compounds and methods for treatment of asthma, allergy and inflammatory disorders
PE20001566A1 (es) 1999-03-26 2001-02-05 Ucb Sa Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP2003508535A (ja) * 1999-09-09 2003-03-04 メルク エンド カムパニー インコーポレーテッド プレニル−タンパク質トランスフェラーゼのインヒビター
WO2003041658A2 (en) 2001-11-13 2003-05-22 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
PT1507531E (pt) * 2003-03-12 2007-03-30 Teva Pharma Composições farmacêuticas estáveis de desloratadina
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
CA2624656A1 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2654847T3 (es) 2006-04-19 2018-02-15 Novartis Ag Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2805945T3 (pl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
AU2011227643A1 (en) 2010-03-16 2012-09-20 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CN112367991A (zh) 2018-06-25 2021-02-12 达纳-法伯癌症研究所股份有限公司 Taire家族激酶抑制剂及其用途
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
KR20250152667A (ko) 2023-03-02 2025-10-23 카르치문 바이오테크 게엠베하 암 및/또는 급성 염증성 질환을 진단하는 수단 및 방법
CN116496259B (zh) * 2023-04-24 2025-08-29 黑龙江珍宝岛药业股份有限公司 一种富马酸卢帕他定的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
WO1992011034A1 (en) * 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance

Also Published As

Publication number Publication date
AU7930994A (en) 1995-05-04
JP2875393B2 (ja) 1999-03-31
EP0723538B1 (en) 2001-12-12
DE69429438D1 (de) 2002-01-24
TW308594B (cg-RX-API-DMAC7.html) 1997-06-21
PT723538E (pt) 2002-05-31
JPH08510759A (ja) 1996-11-12
NZ274749A (en) 1998-05-27
TNSN94104A1 (fr) 1995-09-21
MA23353A1 (fr) 1995-07-01
DE69429438T2 (de) 2002-08-08
EP0723538A1 (en) 1996-07-31
CA2174105A1 (en) 1995-04-20
IL111258A0 (en) 1994-12-29
ES2164716T3 (es) 2002-03-01
ZA947970B (en) 1996-07-12
CA2174105C (en) 2002-02-12
WO1995010515A1 (en) 1995-04-20
HU9600963D0 (en) 1996-06-28
SG48750A1 (en) 1998-05-18
AU699043B2 (en) 1998-11-19
HUT76066A (en) 1997-06-30
ATE210652T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
DK0723538T3 (da) Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme
DK0723540T3 (da) Tricykliske amid- og urinstofderivater til inhibering af funktion af G-protein og til behandling af proliferative sygdomme
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
IL111257A0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
TW349097B (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DK0470221T3 (da) Hidtil ukendte arylethylenderivater og fremgangsmåder til fremstilling deraf
DK0543015T3 (da) Sammensætning, fremgangsmåde og kit til potentiering af antitumorvirkning og til behandling af tumor
NO911121L (no) Nye squalensyntetaseinhibitorer
FI101376B1 (fi) Menetelmä 3-bentsyyliamino-2-fenyylipiperidiinijohdannaisten valmistamiseksi
NO954576D0 (no) AMPA antagonister og en fremgangsmåte til behandling med dem
ATE202354T1 (de) Tetracyclische kondensierte heterocyclische verbindungen zur behandlung von seniler demenz
NO991230D0 (no) Trisykliske forbindelser for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
ATE237611T1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
MY103561A (en) Pestidal method using 2-phenylimidazole derivatives
DK189185A (da) (6,11-dihydro-11-oxodibenz(b,e)oxepinyl)-pentanoler, deres fremstilling og anvendelse